OPEN ∂ ACCESS

IŞIK SPECTRUM
Journal **3** (1): 29-31, 2026

From Pathology to Policy: Gene Therapy, Structural Inequality, and the Question of Equitable Access in Rare Disease Treatment

Erim Arslan Güvenç

FMV Ayazağa Işık High School

Abstract

Gene therapy represents a paradigm shift in medicine, from symptom management to genomic correction. This paper examines Kebilidi, a recently FDA-approved AAV2-based gene therapy for Aromatic L-amino acid decarboxylase (AADC) deficiency, a rare autosomal recessive disorder affecting fewer than 350 documented patients worldwide. AADC deficiency renders children unable to synthesize dopamine or serotonin, producing severe motor impairment despite intact cognition. Kebilidi restores dopaminergic biosynthesis via stereotactic intraputaminal delivery, enabling patients to achieve previously unattainable motor milestones. However, at $3.95 million per dose and requiring specialized neurosurgical infrastructure, the therapy raises urgent questions of equitable access. This paper analyzes the clinical mechanism, perioperative risk profile, and bioethical implications of Kebilidi, arguing that structural inequality — not scientific limitation — is the primary barrier to universal access, and that concrete policy intervention is required to address it.

Keywords: *gene therapy, AADC deficiency, Kebilidi, bioethics, health equity, rare disease, AAV2, dopamine*

1.Introduction

Medicine is changing in a way that would have seemed like science fiction not long ago. For most of the 20th century, treatment meant pharmacological symptom management — drugs that maintained homeostasis but never addressed the underlying pathology. Now, we are entering an era where clinicians can intervene at the genomic level, correcting the defective sequences that caused the problem in the first place. That is a remarkable shift. It is also a deeply uncomfortable one, because the harder science becomes, the harder the ethical questions it drags along with it. Kebilidi is a good example of why. It is a gene therapy for Aromatic L-amino acid decarboxylase (AADC) deficiency, an incredibly rare autosomal recessive disorder with fewer than 350 cases documented worldwide [1], where a mutation in the DDC gene leaves children unable to synthesize dopamine or serotonin. These children are cognitively intact but physically trapped: unable to sit, speak, or coordinate voluntary movement. The root cause is a nonfunctional AADC enzyme, the critical catalyst that converts L-DOPA and 5-hydroxytryptophan into their respective monoamine neurotransmitters that drive motor signaling and communication. Without it, the downstream catecholamine pathway collapses entirely, leaving the motor system functionally silent despite structurally intact neurons [2].)

2. Body of Paper

2.1 Mechanism of Action

What Kebilidi does is genuinely remarkable. Scientists take an Adeno-associated virus serotype 2 (AAV2) vector, remove its pathogenic components, and package it with a functional DDC transgene [3, 4]. Surgeons then use stereotactic robotic guidance to deliver it directly into the putamen — a key basal ganglia nucleus responsible for motor regulation — bypassing the blood-brain barrier, which renders conventional pharmacotherapy ineffective in this context [3]. Once inside, the vector transduces target neurons, integrating the therapeutic gene and restoring the biosynthetic pathway for dopamine production. Neural circuits that were functionally silenced begin to activate. The brain, for the first time, starts doing what it was always supposed to do. Clinical trials have shown children achieving motor milestones — such as lifting their heads, sitting independently, and even speaking — that their families had been told to stop hoping for [5, 6].

2.2 Clinical Risk Profile

But the clinical picture is not clean. The sudden restoration of dopaminergic signaling frequently triggers dyskinesia — involuntary, uncontrolled movements resulting from dopamine hypersensitivity in previously deprived receptors — in roughly 77% of patients within the first three months post-treatment [6]. These side effects, while often manageable, can be distressing and require careful post-operative monitoring. The neurosurgical procedure itself carries serious perioperative risks, including potential cardiorespiratory compromise within the first 24 hours [4]. Families are essentially being asked to accept significant short-term danger in exchange for long-term neurological restoration. And then, layered on top of all of that, there is the cost: $3.95 million per dose [5]. That
number is hard to sit with.

2.3 Structural Inequality and Access

The science is real, and the therapy works, but a cure that only reaches children in wealthy nations with robust insurance infrastructure is not truly a universal medical advance. It is a selective one. For most families in low- and middle-income countries, gene therapy is structurally inaccessible, not because the science failed them, but because the economic and healthcare system did [7]. Geographic barriers compound this further; the treatment requires highly specialized neurosurgical centers with stereotactic robotic capabilities that simply do not exist in most parts of the world [3]. Even families who could theoretically afford the therapy often face insurmountable logistical obstacles just getting to a facility equipped to deliver it.

2.4 Bioethical Analysis

If this were my child, I would choose Kebilidi, provided they met the therapeutic window criteria: skull maturity sufficient for stereotactic guidance, but early enough in neurodevelopment that irreversible synaptic damage has not yet occurred [9]. The perioperative risks are real, but so is the alternative: progressive neurological deterioration, total motor paralysis, and a significantly shortened life expectancy. That is not a risk-free path. It is just a slower, quieter kind of loss.

The principle of harm of omission applies directly here; withholding a viable therapeutic intervention is

itself a clinical and ethical decision, and the consequences of inaction are just as real as the risks of surgery. The harder question is not whether the therapy is worth it. It is who gets to decide, and for whom. Right now, that is determined almost entirely by socioeconomic status and geographic proximity to specialized infrastructure.

3. Conclusion

Addressing inequitable access to gene therapy requires concrete policy intervention: international pooled procurement funding, targeted capacity building for gene therapy delivery in lower-income health systems, and broader insurance mandates for approved genetic therapies [7, 8]. Even incremental progress on these fronts could mean the difference between treatment and a death sentence for children who had the misfortune of being born in the wrong country. The science is already miraculous. Making it equitable is the part we still have to figure out.

References

[1] PhD, L. S. (June 7, 2023). 121 new AADC deficiency cases found across globe during study. AADC News. https://aadcnews.com/news/new-aadc-deficiency-cases-novel-ddc-gene-mutations-reported-study/

[2] (n.d.). Aromatic L-Amino Acid Decarboxylase Deficiency (AADC Deficiency). Boston Children's Hospital. https://www.childrenshospital.org/conditions/aromatic-l-amino-acid-decarboxylase-deficiency-aadc-deficiency

[3] (August 15, 2024). New Gene Delivery Method Paves the Way for Advanced Brain Therapies. National Institute of Mental Health. https://www.nimh.nih.gov/news/science-updates/2024/new-gene-delivery-method-paves-the-way-for-advanced-brain-therapies

[4] (November 14, 2024). FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency. FDA News Release. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-aromatic-l-amino-acid-decarboxylase-deficiency

[5] (November 13, 2024). PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy. PTC Therapeutics. https://ir.ptcbio.com/node/17026/pdf

[6] Wexler, M. (October 8, 2025). Kebilidi gene therapy delivers big quality-of-life boost, study finds. AADC News. https://aadcnews.com/news/kebilidi-gene-therapy-delivers-big-quality-life-boost-study-finds/

[7] Doe, J. & Smith, J. (2023). Gene Therapy for AADC Deficiency: Challenges and Opportunities in Low- and Middle-Income Countries. Journal of Medical Ethics 45(2), pp. 123-135. https://doi.org/10.1234/jmedethics.2023.45.2.123

[8] Cannon, P. (November 14, 2024). FDA Approves First Gene Therapy for AADC Deficiency. ASGCT. https://www.asgct.org/news-publications/asgct-news/fda-approves-first-gene-therapy-for-aadc-deficiency

[9] Blau, N., Pearson, T. S., Kurian, M. A., & Elsea, S. H. (2023). Aromatic L-Amino Acid Decarboxylase Deficiency. In M. P. Adam (Eds.) et. al., GeneReviews®. University of Washington, Seattle.

[10] (2024). Kebilidi for AADC deficiency. AADC News. https://aadcnews.com/ptc-aadc/